Intellia Therapeutics (NTLA) Profit After Tax: 2015-2025
Historic Profit After Tax for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$101.3 million.
- Intellia Therapeutics' Profit After Tax rose 25.34% to -$101.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.8 million, marking a year-over-year increase of 14.64%. This contributed to the annual value of -$519.0 million for FY2024, which is 7.86% down from last year.
- As of Q3 2025, Intellia Therapeutics' Profit After Tax stood at -$101.3 million, which was down 0.07% from -$101.3 million recorded in Q2 2025.
- Over the past 5 years, Intellia Therapeutics' Profit After Tax peaked at -$46.2 million during Q1 2021, and registered a low of -$147.0 million during Q2 2024.
- Its 3-year average for Profit After Tax is -$119.7 million, with a median of -$122.2 million in 2023.
- In the last 5 years, Intellia Therapeutics' Profit After Tax plummeted by 217.87% in 2022 and then soared by 31.11% in 2025.
- Over the past 5 years, Intellia Therapeutics' Profit After Tax (Quarterly) stood at -$81.2 million in 2021, then crashed by 39.60% to -$113.4 million in 2022, then declined by 16.54% to -$132.2 million in 2023, then climbed by 2.47% to -$128.9 million in 2024, then rose by 25.34% to -$101.3 million in 2025.
- Its Profit After Tax was -$101.3 million in Q3 2025, compared to -$101.3 million in Q2 2025 and -$114.3 million in Q1 2025.